Nautilus Biotechnology News

Earnings Call Summary | Nautilus Biotechnology(NAUT.US) Q1 2024 Earnings Conference

The following is a summary of the Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript:Financial Performance:Nautilus Biotechnology reported Q1 2024 total operating expenses of $21.6 m

moomoo AI15:40 ET · Conference Call

Express News | Nautilus Biotechnology Shares Are Trading Higher After the Company Reported Better-than-expected Q1 EPS Results

Benzinga12:03 ET

Express News | Nautilus Biotechnology Inc: Cash, Cash Equivalents, and Investments Were $247.7 Mln as of March 31, 2024

ReutersApr 30 08:09 ET

Express News | Nautilus Biotechnology Reports First Quarter 2024 Financial Results

ReutersApr 30 08:00 ET

Express News | Nautilus Biotechnology Q1 Net Income USD -18.73 Million

ReutersApr 30 08:00 ET

Express News | Nautilus Biotechnology Q1 EPS USD -0.15

ReutersApr 30 08:00 ET

Express News | Nautilus Biotechnology Q1 Operating Expenses USD 21.607 Million

ReutersApr 30 08:00 ET

Press Release: Nautilus Biotechnology Reports First Quarter 2024 Financial Results

Nautilus Biotechnology Reports First Quarter 2024 Financial Results SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a sing

Dow JonesApr 30 08:00 ET

Nautilus Biotechnology Inc (NAUT) Q1 2024 Earnings: Narrower Loss Than Expected

Yahoo FinanceApr 30 07:36 ET

Express News | Nautilus Biotechnology's Cash, Cash Equivalents, And Investments Were $247.7M As Of March 31, 2024

BenzingaApr 30 07:06 ET

Express News | Nautilus Biotechnology Q1 2024 GAAP EPS $(0.15) Beats $(0.17) Estimate

BenzingaApr 30 07:06 ET

Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single molecule protein analysis platform, today announced it will repo

Nautilus BiotechnologyApr 11 00:00 ET

12 Health Care Stocks Moving In Friday's Pre-Market Session

GainersAvalo Therapeutics (NASDAQ:AVTX) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. Xilio Therapeutics (NASDAQ:XLO

BenzingaMar 29 08:06 ET

Nautilus Biotechnology(NAUT.US) 10% Shareholder Buys US$41,477.85 in Common Stocks

$Nautilus Biotechnology(NAUT.US)$ 10% Shareholder Patel Sujal M purchased 14,474 shares of Common Stocks on Mar 8, 11, 2024 at an average price of $2.8657 for a total value of $41,477.85.Source: Annou

moomoo NewsMar 11 21:01 ET

This Nautilus Biotechnology Insider Increased Their Holding In The Last Year

Yahoo FinanceMar 11 07:07 ET

Sujal Patel Buys Handful Of Shares In Nautilus Biotechnology

Even if it's not a huge purchase, we think it was good to see that Sujal Patel, the Co-Founder of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) recently shelled out US$99k to buy stock, at US$2.79 per sh

Simply Wall StMar 11 06:00 ET

Nautilus Biotechnology(NAUT.US) 10% Shareholder Buys US$99,054.42 in Common Stocks

$Nautilus Biotechnology(NAUT.US)$ 10% Shareholder Patel Sujal M purchased 35,526 shares of Common Stocks on Mar 5, 6, 7, 2024 at an average price of $2.7882 for a total value of $99,054.42.Source: Ann

moomoo NewsMar 7 19:49 ET

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2023 Earnings Call Transcript

Yahoo FinanceFeb 29 09:41 ET

Earnings Call Summary | Nautilus Biotechnology(NAUT.US) Q4 2023 Earnings Conference

The following is a summary of the Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript:Financial Performance:Nautilus Biotechnology reported Q4 operating expenses of $20.0 million, lar

moomoo AIFeb 28 16:24 ET · Conference Call

Nautilus Biotechnology Files $300M Mixed Securities Shelf

Seeking AlphaFeb 28 15:51 ET